Literature DB >> 22012023

Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.

Eun-ju Kim1, Su-Kyoung Ko, Hye-Young Kang.   

Abstract

PURPOSE: To develop a mapping algorithm for a conversion of the EORTC QLQ-C30 and EORTC QLQ BR-23 into the EQ-5D-derived utilities in metastatic breast cancer (MBC) patients.
METHODS: We enrolled 199 patients with MBC from four leading Korean hospitals in 2009. EQ-5D utility, cancer-specific (QLQ-C30) and breast cancer-specific quality of life data (QLQ-BR23) and selected clinical and demographic information were collected from the study participants. Ordinary least squares regression models were used to model the EQ-5D using QLQ-C30 and QLQ-BR23 scale scores. To select the best model specification, six different sets of explanatory variables were compared. RESULT: Regression analysis with the multiitem scale scores of QLQ-C30 was the best-performing model, explaining for 48.7% of the observed EQ-5D variation. Its mean absolute error between the observed and predicted EQ-5D utilities (0.092) and relative prediction error (2.784%) was among the smallest. Also, this mapping model showed the least systematic errors according to disease severity.
CONCLUSIONS: The mapping algorithms developed have good predictive validity, and therefore, they enable researchers to translate cancer-specific health-related quality of life measures to the preference-adjusted health status of MBC patients.

Entities:  

Mesh:

Year:  2011        PMID: 22012023     DOI: 10.1007/s11136-011-0037-y

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  17 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences.

Authors:  Ralph Crott; Andrew Briggs
Journal:  Eur J Health Econ       Date:  2010-05-16

Review 3.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures.

Authors:  John E Brazier; Yaling Yang; Aki Tsuchiya; Donna Louise Rowen
Journal:  Eur J Health Econ       Date:  2009-07-08

4.  Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

Authors:  Helen Dakin; Stavros Petrou; Mark Haggard; Sarah Benge; Ian Williamson
Journal:  Qual Life Res       Date:  2009-11-26       Impact factor: 4.147

5.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

Authors:  M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

6.  Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.

Authors:  J M Borras; A Sanchez-Hernandez; M Navarro; M Martinez; E Mendez; J L Ponton; J A Espinas; J R Germa
Journal:  BMJ       Date:  2001-04-07

7.  Mapping utility scores from a disease-specific quality-of-life measure in bariatric surgery patients.

Authors:  Stefan Sauerland; Sylvia Weiner; Karin Dolezalova; Luigi Angrisani; Carlos Masdevall Noguera; Manuel García-Caballero; Frédéric Rupprecht; Marc Immenroth
Journal:  Value Health       Date:  2009 Mar-Apr       Impact factor: 5.725

Review 8.  International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience.

Authors:  Andrew Bottomley; Neil K Aaronson
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

9.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

10.  Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data.

Authors:  Lynda McKenzie; Marjon van der Pol
Journal:  Value Health       Date:  2008-07-11       Impact factor: 5.725

View more
  24 in total

1.  Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.

Authors:  Admassu N Lamu; Jan Abel Olsen
Journal:  Qual Life Res       Date:  2018-09-01       Impact factor: 4.147

2.  Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.

Authors:  Hosein Ameri; Mahmood Yousefi; Mehdi Yaseri; Azin Nahvijou; Mohammad Arab; Ali Akbari Sari
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 3.  A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.

Authors:  Jihyung Hong; Eun-Young Bae
Journal:  Pharmacoeconomics       Date:  2021-07-28       Impact factor: 4.981

4.  Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.

Authors:  Brett Doble; Paula Lorgelly
Journal:  Qual Life Res       Date:  2015-09-21       Impact factor: 4.147

5.  Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.

Authors:  Tong Liu; Shunping Li; Min Wang; Qiang Sun; Gang Chen
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

6.  Mapping of the OAB-SF Questionnaire onto EQ-5D in Spanish Patients with Overactive Bladder.

Authors:  Miguel A Ruiz; Laura L Gutiérrez; Manuel Monroy; Javier Rejas
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

7.  Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.

Authors:  Vakaramoko Diaby; Georges Adunlin; Askal Ayalew Ali; Rima Tawk
Journal:  Breast Cancer Res Treat       Date:  2014-07-14       Impact factor: 4.872

8.  Pain, Sleep Disturbance, and Quality of Life Among Palestinian Patients Diagnosed with Cancer.

Authors:  Mu'taz M Dreidi; Ayman M Hamdan-Mansour
Journal:  J Cancer Educ       Date:  2016-12       Impact factor: 2.037

9.  Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool.

Authors:  Stefano Maratia; Sergio Cedillo; Javier Rejas
Journal:  Qual Life Res       Date:  2016-04-05       Impact factor: 4.147

10.  Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.

Authors:  Seon Ha Kim; Min-Woo Jo; Hwa-Jung Kim; Jin-Hee Ahn
Journal:  Health Qual Life Outcomes       Date:  2012-12-17       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.